European journal of clinical pharmacology
-
Eur. J. Clin. Pharmacol. · Mar 2010
Drug utilization and off-label drug use among Spanish emergency room paediatric patients.
To describe the use of medicines and to determine the frequency of off-label use in emergency room paediatric patients. ⋯ Although the mean number of drugs used in children is small, off-label use is frequent. Research efforts should target paediatric studies that allow a rational drug use in children.
-
Eur. J. Clin. Pharmacol. · Feb 2010
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.
The aim of the present study was to collect and compare cases of drug-induced PML in order to contribute to the debate about the role of the underlying diseases and/or drug immunosuppression in PML occurrence. ⋯ We found a strong relationship between PML and MAbs, especially when used in autoimmune diseases. PML is becoming a crucial issue of MAbs, since they can cause severe ADRs through the imbalance of the immune system. Based on these results, patients treated with MAbs should be carefully monitored for early signs and symptoms of PML.
-
Eur. J. Clin. Pharmacol. · Feb 2010
Letter Case ReportsProlonged hyperthermia from furosemide infusion--a case report.
-
Eur. J. Clin. Pharmacol. · Jan 2010
CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients.
To investigate whether the CYP3A4*1G genetic polymorphism contributes to the variability in CYP3A activity and response to fentanyl. ⋯ CYP3A4*1G genetic polymorphism decreases CYP3A activity and fentanyl consumption for postoperative pain control.
-
Eur. J. Clin. Pharmacol. · Jan 2010
Multicenter StudyPopulation pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months.
Until recently, ondansetron was approved for the prevention of nausea and vomiting only in patients older than 2 years. However, as the use of ondansetron in patients younger than 2 years had been documented, characterization of ondansetron pharmacokinetics in this younger pediatric age group was warranted. ⋯ The population pharmacokinetic analysis of ondansetron allows for characterization of individual patients based on body weight and age. It is recommended that patients younger than 4 months receiving ondansetron be closely monitored.